Healthcare

Definium Therapeutics (NASDAQ:DFTX) was indicated to be up 5.24% in the October 9, 2026 premarket session on the screener, on a displayed price of USD 34.18 and pre-market volume of 2,978 shares. The screener lists no catalyst, and a search identified noBusinessdisclosure or filing …

Pfizer (NYSE:PFE) stated the FDA approved Tukysa, known generically as tucatinib, for first-line maintenance treatment in HER2-favorable breast cancer. The supporting figure is progression-free survival of 24.9 months versus 16.3 months for the comparison group. Progression-free survival measures how long patients live without their …

argenx (NASDAQ:ARGX) stated it is discontinuing a late-stage trial of efgartigimod in Sjogren's disease because the study did not demonstrate enough efficacy, according to a listedBusinessdisclosure disclosed on October 8, 2026. The shares declined, but the source material provides no the size of the …

Atrium Therapeutics (NASDAQ:RNA) was indicated to be down 3.15% in the October 9, 2026 premarket session on the screener, on a displayed price of USD 8.26. The cause is an issuer disclosure dated October 8, 2026 of a privatePlacementwith anticipated gross proceeds of approximately …

Clover Health (NASDAQ:CLOV) was indicated to be up 11.35% in the October 9, 2026 premarket session on the screener, on a displayed price of USD 4.58 and pre-marketVolumeof 40,045 shares. The screener tags the catalyst as news, but a search located no business statement, …

Bristol Myers Squibb (NYSE:BMY) noted a Phase 3 trial of Zenbexus demonstrated a 51% cut in the exposure to disease progression in multiple myeloma, a cancer of plasma cells in the bone marrow, according to a listed business statement disclosed on October 8, 2026. …

XORTX Therapeutics (NASDAQ:XRTX) stated it has received more inquiries about commercialization and has made progress on a trial application with Health Canada, according to an issuer statement disclosed around October 9, 2026. The stock advanced roughly 22% in after-hours trading. The issuer's market capitalization …